However, a study suggests that S100A6 expression and its post-translational modifications correlate with improved outcomes in stage 1 NSCLC patients, especially in tumors without p53 expression, suggesting a pro-apoptotic role and potential interactions with p53 (119). Here, S100A6 is linked to non-small cell lung carcinoma.